.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AB11_PeginterferonAlfa2a.PeginterferonAlfa2a .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AB11_PeginterferonAlfa2a.PeginterferonAlfa2a| name: | PeginterferonAlfa2a |
| ATC code: | L03AB11 | route: | subcutaneous |
| n-compartments | 1 |
Peginterferon alfa-2a is a pegylated form of interferon alfa-2a, an immunomodulatory drug used primarily in the treatment of chronic hepatitis B and C infections. By attaching polyethylene glycol (PEG) to interferon alfa-2a, the drug has an extended half-life, allowing for less frequent dosing. Peginterferon alfa-2a is approved and widely used for antiviral therapy, though its use has decreased with the advent of newer direct-acting antivirals for hepatitis C.
Pharmacokinetic parameters reported for adults with chronic hepatitis C, both male and female, under standard clinical dosing.
Jung, YS, et al., & Park, K (2018). Population PK-PD Model of Pegylated Interferon Alfa-2a in Healthy Korean Men. Journal of pharmaceutical sciences 107(12) 3171–3178. DOI:10.1016/j.xphs.2018.08.017 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30179597
Keating, GM, & Curran, MP (2003). Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs 63(7) 701–730. DOI:10.2165/00003495-200363070-00008 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12656650
Howell, CD, et al., & Hoofnagle, JH (2008). Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 6(5) 575–583. DOI:10.1016/j.cgh.2008.02.035 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18407798